Celgene

BMS re-ups 'highly productive' legacy neurodegeneration partnership with Evotec for $50M upfront
BMS re-ups 'highly productive' legacy neurodegeneration partnership with Evotec for $50M upfront
Fierce Biotech
Bristol Myers Squibb
Celgene
Evotec
neurodegenerative disease
Flag link:
Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over
Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over
Fierce Pharma
Bristol Myers Squibb
Breyanzi
Celgene
legal
M&A
CVRs
Flag link:
'Monopoly' allowed Bristol Myers and generics makers to 'steal' from Revlimid purchasers, lawsuit says
'Monopoly' allowed Bristol Myers and generics makers to 'steal' from Revlimid purchasers, lawsuit says
Fierce Pharma
Bristol Myers Squibb
Celgene
Revlimid
patents
generics
Flag link:
Federal judge denies Bristol Myers' attempt to avoid Celgene shareholder lawsuit
Federal judge denies Bristol Myers' attempt to avoid Celgene shareholder lawsuit
Endpoints
Celgene
Bristol Myers Squibb
Breyanzi
legal
Flag link:
Bristol Myers dusts off an old Celgene chemotherapy for use in children with a rare blood cancer
Bristol Myers dusts off an old Celgene chemotherapy for use in children with a rare blood cancer
Endpoints
Bristol Myers Squibb
Celgene
chemotherapy
FDA
Vidaza
MDS
Flag link:
Bristol Myers Squibb, after massive Celgene takeover, plots $15B buyback plan
Bristol Myers Squibb, after massive Celgene takeover, plots $15B buyback plan
Fierce Pharma
Bristol Myers Squibb
Celgene
M&A
stock buybacks
Flag link:
Next-gen psoriasis drug rivalry between Bristol Myers and Nimbus spills into a legal battle
Next-gen psoriasis drug rivalry between Bristol Myers and Nimbus spills into a legal battle
Endpoints
Bristol Myers Squibb
Celgene
Nimbus Therapeutics
psoriasis
deucravacitinib
Flag link:
Bristol Myers inks another Revlimid patent settlement—this time with Sun Pharma—as copycats near
Bristol Myers inks another Revlimid patent settlement—this time with Sun Pharma—as copycats near
Fierce Pharma
Bristol Myers Squibb
Celgene
Revlimid
generics
Sun Pharma
patents
Flag link:
Bristol-Myers is sued for $6.4 billion over delayed cancer drug
Bristol-Myers is sued for $6.4 billion over delayed cancer drug
Reuters
Bristol Myers Squibb
Breyanzi
legal
Celgene
Flag link:
Bristol Myers expands Celgene-era deal with Exscientia, taking its AI R&D engine to the next step
Bristol Myers expands Celgene-era deal with Exscientia, taking its AI R&D engine to the next step
Endpoints
Bristol Myers Squibb
Exscientia
R&D
Celgene
M&A
artificial intelligence
Flag link:
Bristol’s buy moves it to the top of the sales charts
Bristol’s buy moves it to the top of the sales charts
EP Vantage
Celgene
Bristol-Myers Squibb
M&A
sales reps
Flag link:
How Bristol Myers Squibb's Celgene Buyout Continued to Pay Off in Q4
How Bristol Myers Squibb's Celgene Buyout Continued to Pay Off in Q4
Motley Fool
Bristol-Myers Squibb
Celgene
earnings
M&A
Flag link:
Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug
Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug
Endpoints
Bristol-Myers Squibb
Celgene
FDA
ulcerative colitis
priority review
Zeposia
Flag link:
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020
FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020
Fierce Pharma
Bristol-Myers Squibb
Celgene
liso-cel
M&A
CAR-T
Flag link:
BMS/Celgene merger payout evaporates as CVR deadline passes
BMS/Celgene merger payout evaporates as CVR deadline passes
Pharmaforum
Celgene
Bristol-Myers Squibb
FDA
CVRs
Flag link:
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
Endpoints
Bristol-Myers Squibb
liso-cel
drug manufacturing
Celgene
CVRs
Flag link:
Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again
Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again
Endpoints
Bristol-Myers Squibb
CVRs
Celgene
M&A
Flag link:
Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches
Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches
Fierce Pharma
Celgene
Bristol-Myers Squibb
Zeposia
Reblozyl
Onureg
Flag link:
[video+transcript]Here's What's Behind Bristol Myers Squibb's Huge Acquisitions
[video+transcript]Here's What's Behind Bristol Myers Squibb's Huge Acquisitions
Motley Fool
Bristol-Myers Squibb
M&A
Celgene
MyoKardia
Flag link:
Celgene shareholders are parsing blurry photos in search of a payday
Celgene shareholders are parsing blurry photos in search of a payday
Stat
Celgene
Bristol-Myers Squibb
FDA
M&A
Flag link:

Pages